Patient-Derived Xenografts

Patient-Derived Xenografts

Methods and Protocols

Saad, Mohamed I.

Springer-Verlag New York Inc.

04/2024

244

Dura

9781071638576

15 a 20 dias

Descrição não disponível.
Patient-Derived Xenografts: Historical Evolution, Immunocompromised Host Models, and Translational Significance.- Patient-Derived Xenograft Models in Cancer Research: Methodology, Applications, and Future Prospects.- Patient-Derived Xenografts: A Valuable Preclinical Model for Drug Development and Biomarker Discovery.- Patient-Derived Xenograft Models for Leukemias.- Patient-Derived Orthotopic Xenograft Models for High-Grade Pediatric Brain Cancers.- Generation of Orthotopic and Subcutaneous Patient-Derived Xenograft Models from Diverse Clinical Tissue Samples of Pediatric Extracranial Solid Tumors.- Development of Orthotopic Patient-Derived Xenograft Models of Pediatric Intracranial Tumors.- A Humanized Patient-Derived Xenograft Model for Pancreatic Cancer.- Development and Expansion of Patient-Derived Xenografts for Endometrial Cancer.- A Multiplexed Approach to Assess Small Cell Lung Cancer Subtype Heterogeneity in Primary and Patient-Derived Tumor Samples.- Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models.- Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.- Patient-Derived Xenograft Models for Ovarian Cancer.- Orthotopic MC-38 Allograft as a Robust Preclinical Model of Colorectal Carcinoma.- Assessing Protein Expression in Patient-Derived Xenografts Using Western Blotting.- Analysis of Protein Interactions in Patient-Derived Xenografts Using Immunoprecipitation.- A Semi-Automated Proteomics and Phosphoproteomics Protocol for the Identification of Novel Therapeutic Targets and Predictive Biomarkers in In Vivo Xenograft Models of Pediatric Cancers.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
PDXs;Cancer therapeutics;Translational cancer research;Clinical tissue samples;Cancer types;Protein expression;Predictive biomarkers;Drug development